Background-The impact of apixaban versus aspirin on ischemic stroke and major bleeding in relation to the CHADS 2 and CHA 2 DS 2 -VASc stroke risk scores in atrial fibrillation has not been investigated. Methods and Results-In this secondary analysis of the AVERROES trial, our principal objective was to assess the effect of treatment with aspirin or apixaban on ischemic stroke and major bleeding, in relation to the CHADS 2 /CHA 2 DS 2 -VASc scores. We found no significant heterogeneity for treatment efficacy on ischemic stroke for apixaban when subdivided by stroke risk strata, based on CHADS 2 /CHA 2 DS 2 -VASc. Effects were consistent irrespective of baseline risk, and thus, absolute benefits were greatest in the high-risk groups. There was also no significant heterogeneity for apixaban versus aspirin with regard to major bleeding, when subdivided by CHADS 2 /CHA 2 DS 2 -VASc scores. In multivariable analysis, significant predictors of stroke on aspirin were age ≥75 years, prior stroke or transient ischemic attack, estimated glomerular filtration rate <60 mL/min, and nonparoxysmal atrial fibrillation. Proportions of the study cohort classified as low/moderate/ high risk using the CHADS 2 and CHA 2 DS 2 -VASc scores were 0.3%/71.7%/28.1% and <0.1%/10.5%/89.5%, respectively. Conclusions-In an atrial fibrillation population, apixaban was superior to aspirin for stroke prevention, with similar rates of major bleeding, in the presence of one or more stroke risk factors, with consistency of the treatment effect by CHADS 2 / CHA 2 DS 2 -VASc scores. Clinical Trial Registration Information-clinicaltrials.gov; Identifier: NCT00496769. (Circ Arrhythm Electrophysiol. 2013;6:31-38.)
T he presence of atrial fibrillation (AF) increases the risk of stroke and thromboembolism, but this risk is not homogeneous. In everyday clinical practice, there is the need for clinicians to balance the benefits and risks of anticoagulation, when considering stroke prevention in patients with AF. 1 Until recently, stroke risk stratification schemes were developed to assist clinicians identify high-risk patients who could be treated with warfarin. With the availability of new oral anticoagulants that offer superior efficacy and safety, new stroke risk stratification aim to be better at identifying low-risk patients who may not need any antithrombotic therapy, whereas those with one or more stroke risk factors can be considered for oral anticoagulant therapy. 1
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Importantly, risk factors for stroke change over time because of better control of blood pressure and better treatments for heart failure, which raises questions about the adequacy of existing stroke risk prediction schemes; indeed, even young subjects classified as lone AF at baseline are at risk of thromboembolism when these subjects develop new risk factors. 2 The well-validated CHADS 2 score is risk stratification score first published in 2001, and is a score that includes 5 common stroke risk factors: Congestive heart failure, Hypertension, Age ≥75, Diabetes and prior Stroke, the latter getting 2 points. 3 The pros and cons of the CHADS 2 score have been highlighted, particularly the fact that a CHADS 2 score of 0 to 1 is not low risk. 4, 5 The newer CHA 2 DS 2 -VASc score (Cardiac failure or dysfunction, Hypertension, Age ≥75 [Doubled], Diabetes, Stroke [Doubled]-Vascular disease, Age 65-74 and Sexcategory [Female]) differs from the CHADS 2 score by including additional common stroke risk factors (age 65-74, vascular disease, female sex) and giving extra weight to age ≥75 as a risk factor. 6 The CHA 2 DS 2 -VASc score has also been well validated. 6, 7 The principal objective of the present analysis was to assess the effect of treatment with aspirin or apixaban on ischemic stroke, in relation to CHADS 2 and the CHA 2 DS 2 -VASc scores. As a secondary analysis, we identified risk factors for stroke in this dataset of a large contemporary clinical study, the AVERROES trial 8 among aspirin-and apixaban-treated patients.
Methods

Study Population
The rationale, design, and results of the AVERROES trial (ClinicalTrials.gov number, NCT00496769) have been published. 5 In summary, this was a randomized, multicenter, parallel group trial that compared apixaban (at a dose of 5 mg twice daily, with a dose adjustment to 2.5 mg bid for selected patients) or aspirin (81-324 mg per day) for the prevention of stroke and systemic embolism in patients with nonvalvular persistent paroxysmal or permanent AF at moderate to high risk of stroke, who had declined, failed anticoagulation use, or for whom anticoagulation was deemed unsuitable. The mean followup period was 1.1 years. The primary outcome was the occurrence of stroke or systemic embolism. The primary event rate was 1.6% per year among patients assigned to apixaban and 3.6% per year among those treated with aspirin (hazard ratio with apixaban, 0.45; 95% confidence interval, 0.32-0.62; P<0.001). Thus, apixaban reduced the risk of stroke or systemic embolism without significantly increasing the risk of major bleeding or intracranial hemorrhage (ICH).
Definitions of Outcomes
The primary efficacy outcome of AVERROES was stroke (ischemic, hemorrhagic, or unspecified) or systemic embolism. Stroke was a clinical diagnosis that was made on the basis of typical symptoms lasting at least 24 hours. Brain imaging was required to differentiate ischemic from hemorrhagic events. Ischemic stroke was the main outcome of interest for this ancillary analysis.
The primary safety outcome was major bleeding, defined as clinically overt bleeding accompanied by one or more of the following: a decrease in the hemoglobin level of 2 g per dL or more over a 24-hour period, transfusion of 2 or more units of packed red cells, bleeding at a critical site (intracranial, intraspinal, intraocular, pericardial, intraarticular, intramuscular with compartment syndrome, or retroperitoneal), or fatal bleeding.
The CHADS 2 and CHA 2 DS 2 -VASc schemes are point-based scores. The CHADS 2 is based on 1 point for congestive heart failure, hypertension, age 75 years or older and diabetes mellitus, and 2 points for prior stroke or transient ischemic attack (TIA). We defined the CHADS 2 score risk categories in 2 ways: (a) classical, whereby scores of 0=low, 1 to 2=intermediate, >2=high risk; or (b) revised, whereby scores of 0=low, 1=intermediate, ≥2=high risk. Although not the primary focus of the new scheme when first proposed, the CHA 2 DS 2 -VASc score categories a score 0=low, 1=intermediate, and ≥2 as high risk.
Statistical Analyses
Analyses were conducted according to the intention-to-treat principle. All randomized patients were included in the analysis. The outcome events were observed from randomization until either study closure or loss to follow-up or death irrespective of continuation of treatment actually received. Patients were kept in the treatment group to which they were randomized.
Rates of ischemic stroke and major bleeding per 100 patient-years of follow-up were estimated for the following categories of the 2 investigated risk stratification schemes: CHADS 2 score (0-1, 2, 3-6) and CHA 2 DS 2 -VASc score (0-1, 2, 3-5, 6-8). Hazard ratios for the effect of treatment with apixaban versus aspirin according to CHADS 2 and CHA 2 DS 2 -VASc risk category were estimated using separate Cox proportional hazards regression models fitted within each category. Interaction between treatment with apixaban and CHADS 2 or CHA 2 DS 2 -VASc risk category was tested in the Cox model fitted to all patients.
Univariate Cox proportional hazards regression models were used to investigate the impact of individual risk factors on the risk of ischemic stroke, in patients treated with aspirin or apixaban: age (<75, ≥75 years), sex, body mass index (<25, 25-31, >31 kg/m 2 ), prior stroke or TIA, hypertension, diabetes melltus, heart failure or left ventricular ejection fraction ≤35%, peripheral artery disease, type of AF (paroxysmal, persistent, permanent), and estimated glomerular filtration rate (<60, ≥60 mL/min). All potential stroke risk factors were subsequently included in the multivariable Cox model. Analyses were performed using SAS software, version 9.2 of the SAS System for SunOS (SAS Institute Inc, Cary, NC).
Results
Patients and clinical demographic characteristics of the whole-trial cohort (n=5599) and the 2 treatment groups are shown in Table 1 . The mean CHADS 2 score was 2.1 There was no significant heterogeneity for the treatment effect of apixaban versus aspirin on ischemic stroke, in relation to stroke risk strata by the CHADS 2 and CHA 2 DS 2 -VASc scores ( Table 2 and Figure 1 ). For safety, there was also no significant heterogeneity for apixaban versus aspirin with regard to major bleeding, when subdivided by CHADS 2 and CHA 2 DS 2 -VASc scores ( Table 3 and Figure 2 ).
In the aspirin-treated patients, the proportions of the cohort classified as low/moderate/high risk using the CHADS 2 score (classical) were 0.3%, 71.7%, and 28.1%; for CHADS 2 score (revised) these were 0.3%, 35.9%, and 63.8%, and corresponding proportions for CHA 2 DS 2 -VASc score were 0.02%, 10.5%, and 89.5%, respectively (Table 4 ).
In univariate analysis, ischemic stroke risk in the aspirintreated patients was significantly associated with age ≥75 years (P<0.001), female sex (P=0.01), prior stroke or TIA (P<0.001), estimated glomerular filtration rate (P<0.001), and nonparoxysmal arrhythmia (P<0.001), but not hypertension, body mass index, heart failure, or peripheral artery disease ( Table 5 ). In apixaban-treated patients, the effects of age ≥75 years, female sex, and prior stroke or TIA were similar in magnitude, although not statistically significant ( Table 5 ). Diabetes mellitus, nonparoxysmal AF, and estimated glomerular filtration rate 9 showed the largest differences in their effect on the ischemic stroke between patients treated with aspirin and apixaban ( Table 5) .
In multivariable analysis, significant predictors of ischemic stroke on aspirin were age (P=0.001), prior stroke or TIA (P=0.004), estimated glomerular filtration rate (P=0.03), and nonparoxysmal AF (P=0.03). Among apixaban-treated patients, only diabetes mellitus emerged as a significant independent predictor for ischemic stroke in multivariate analysis (P=0.05; Table 6 ). As expected, ischemic stroke rates increased with increasing CHADS 2 and CHA 2 DS 2 -VASc scores, in both aspirin-and apixaban-treated patients (all P<0.001; Table 7 ). CHA 2 DS 2 -VASc score showed stronger association with the risk of ischemic stroke than CHADS 2 score (Table 7 ).
Discussion
Our principal observation from this article is that apixaban was superior to aspirin, irrespective of stroke risk strata (as assessed by CHADS 2 and CHA 2 DS 2 -VASc scores). For safety, we also show no significant heterogeneity for apixaban versus aspirin with regard to major bleeding, when subdivided by stroke risk strata. In a multivariable analysis, we show an increase in stroke risk is seen with age, prior stroke, and renal dysfunction in this contemporary aspirintreated cohort.
In the primary analysis of the AVERROES trial, 8 apixaban was superior to aspirin for stroke prevention, with no significant difference in major bleeding (or ICH) rates, and importantly, aspirin was less well tolerated (as reflected by permanent drug discontinuations) compared with the anticoagulant, apixaban. We have extended this observation by demonstrating that there was no significant heterogeneity for the treatment effect for efficacy and safety for apixaban over aspirin, irrespective of stroke risk strata in relation to the CHADS 2 and CHA 2 DS 2 -VASc scores. Given the broad range of patients studied in AVERROES, and given the similar rates of major bleeding and its superior efficacy, apixaban should be the treatment choice in patients with one or more stroke risk factors, instead of aspirin.
Aspirin appears to have limited efficacy for stroke prevention in AF in the elderly and is associated with rates of major bleeding and adverse events that are similar or even worse than warfarin. [10] [11] [12] If there is an interaction between age and aspirin for the outcomes of bleeding and stroke, it was not evident even in large contemporary trials, such as AVERROES. Indeed, in AVERROES, aspirin was even less well tolerated compared with the anticoagulant treatment. have recommended no antithrombotic therapy for patients at truly low risk, whereas for those with one or more stroke risk factors, oral anticoagulation (whether with well-controlled vitamin K antagonist or a new anticoagulant drug) is recommended or preferred therapy. 13 The potential benefit from stroke prevention has to be balanced against the risk of bleeding, and ICH is the most feared complication of oral anticoagulation therapy. 14 Bleeding risk is minimized by well-controlled warfarin (with high time in therapeutic range), 15 although new oral anticoagulants have lower rates of ICH compared with vitamin K antagonist therapy irrespective of International Normalised Ratio (INR) control. 16, 17 In this analysis, there was no significant heterogeneity for major bleeding with apixaban versus aspirin, when stratified by stroke risk strata. Thus, apixaban is clearly superior for stroke prevention, with similar rates of major bleeding, compared with aspirin-and this is irrespective of stroke risk strata (as defined by CHADS 2 and CHA 2 DS 2 -VASc scores).
In a Markov decision analysis model balancing the relative hazard of ischemic stroke against the relative hazard of ICH, anticoagulation with a new, safer drug could even be used at ischemic stroke rates of 0.9%/year. 18 One recent analysis in a large nationwide cohort study clearly confirms that the net clinical benefit weighing ischemic stroke against ICH is negative only in truly low-risk subjects (defined as a CHA 2 DS 2 -VASc score=0), whereas with CHADS 2 , the net clinical benefit with CHADS 2 was neutral (scores=0) and positive (≥1) for warfarin therapy. 19 Of note, a CHADS 2 score=0 is not truly low risk, as the (nonanticoagulated) stroke rate can range between 0.8%/year to 3.2%/year, when such patients are substratified by CHA 2 DS 2 -VASc score. 5 Our findings that apixaban was superior to aspirin, irrespective of stroke risk strata would support the use of effective stroke prevention (that is, oral anticoagulation-rather than aspirin) in AF patients with ≥1 stroke risk factors.
Stroke risk in AF is not homogeneous, and is dependent on the presence of various stroke risk factors. In the systematic review from the Stroke Risk in AF Working Group, 20 significant predictors of stroke were age (1.5-fold per decade, from age 65 upwards), prior stroke/TIA, hypertension, diabetes mellitus, and female sex; however, this analysis was largely driven by data from nonvitamin K antagonist arms of the historical randomized trials from 2 decades ago (which had various limitations, for example, only <10% of those screened were randomized) and a few cohort studies. In this contemporary clinical trial cohort, significant predictors of stroke on aspirin were age, prior stroke/TIA, creatinine clearance, and nonparoxysmal AF on multivariate analysis, which is largely consistent with the literature for age, prior stroke, and creatinine clearance. 21 There were no significant univariate predictors of stroke risk among the apixaban-treated patients, although body mass index was a predictor on multivariate analysis.
Interestingly, history of hypertension, diabetes mellitus, and heart failure seem to factor less in the present analysis, compared with historical cohorts. However, this could partly be because of the exclusion of patients with no risk factors from AVERROES. Well-controlled hypertension is associated with a low risk of stroke, and more contemporary studies clearly show that only uncontrolled blood pressure represents a stroke risk factor in AF. 22, 23 Also, the impact of diabetes mellitus on stroke risk in AF was not considered significant in the National Institute for Health and Clinical Excellence (NICE) systematic review, 24 although it was considered a risk factor in the Stroke in AF Working Group analysis. 20 Finally, history of heart failure has been regarded as a nonsignificant stroke risk factor, 20 although the presence of moderate to severe systolic dysfunction is clearly associated with stroke. 25 The multivariable predictors of ischemic stroke are consistent with recent studies highlighting the importance of age and renal dysfunction driving stroke risk. 26, 27 The observation that paroxysmal AF was associated with a lower stroke risk is at variance with other evidence and guideline recommendations, 13, 28 where paroxysmal AF patients should be offered thromboprophylaxis in a similar manner to nonparoxysmal AF patients in association with stroke risk factors. We did not quantify arrhythmia burden in AVERROES, and whereas patients with paroxysmal AF needed one documented episode of AF in the preceding 6 months prior to study entry, the possibility remains that some patients had low AF burden to the extent that their stroke risk was correspondingly low. Indeed, arrhythmia burden has been shown to improve clinical risk assessment using the CHADS 2 score. 29 Unsurprisingly, stroke rates increased with increasing CHADS 2 and CHA 2 DS 2 -VASc scores, in both aspirinand apixaban-treated patients. 
Limitations
This study is limited by its dependence on a trial population, which may have a package-of-care of careful follow-up and management of assessment of associated cardiovascular risk factors. Hence, event rates may be lower than that seen in realworld clinical practice. Also, patients were entered into AVER-ROES on the basis of ineligibility or refusal to take vitamin K antagonist, and thus, residual confounding may remain given that these patients may be perceived to be unsuitable for warfarin, or where contraindications may be evident at study entry but not adequately addressed (eg, uncontrolled hypertension). Thus, our data may not be generalizable to all patients with AF. Nonetheless, the patient characteristics of AVERROES were broadly similar to those entering other contemporary clinical trials, such as RE-LY and ARISTOTLE.
Conclusion
In a contemporary clinical trial AF population, apixaban was superior to aspirin for stroke prevention, with similar rates of major bleeding, in the presence of one or more stroke risk factors, with consistency of the treatment effect by CHADS 2 and CHA 2 DS 2 -VASc scores.
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